Targeting the lymphatics using dendritic polymers (dendrimers)

Advanced Drug Delivery Reviews

Volumn 63, Issue 10-11, 2011, Pages 890-900

  Kaminskas, Lisa M ^a   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Bioavailability; Dendrimer; Drug delivery; Lymphangiography; Lymphatic transport; Magnetic resonance imaging; Pharmacokinetics; Polymer; Protein

Indexed keywords

BIOAVAILABILITY; BIOMEDICAL APPLICATIONS; CENTRAL CORE; DISEASE PROGRESSION; DRUG-TARGETING; IMAGING AGENT; LYMPH NODE; LYMPHANGIOGRAPHY; LYMPHATIC SYSTEMS; LYMPHATIC TRANSPORT; OPTICAL FLUORESCENCE; RECIRCULATIONS; SYSTEMIC CIRCULATION;

ANGIOGRAPHY; BIOCHEMISTRY; BIOLOGICAL MATERIALS; DENDRIMERS; DRUG DELIVERY; HYDROPHILICITY; MAGNETIC RESONANCE IMAGING; MEDICAL APPLICATIONS; MICROCIRCULATION; PHARMACOKINETICS; RESONANCE;

FUNCTIONAL POLYMERS;

ALBUMIN; ALBUMIN I 125; AVIDIN; BENZENESULFONIC ACID DERIVATIVE; DENDRIMER; DEXTRAN; ERYTHROPOIETIN; GADOLINIUM; GADOLINIUM POLYAMIDOAMINE; HUMAN GROWTH HORMONE; IMMUNOGLOBULIN G; MACROGOL; MACROGOL 200; MACROGOL 2000; MACROGOL 570; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PEGYLATED POLYLYSINE; POLYPROPYLENEIMINE; UNCLASSIFIED DRUG;

CONJUGATION; DRUG CLEARANCE; DRUG UPTAKE; HYDROPHOBICITY; LYMPH NODE; LYMPH VESSEL; LYMPHANGIOGRAPHY; LYMPHATIC SYSTEM; MAGNETIC RESONANCE LYMPHANGIOGRAPHY; MOLECULAR SIZE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; SURFACE CHARGE;

ANIMALS; BIOLOGICAL TRANSPORT; DENDRIMERS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHATIC SYSTEM; LYMPHOGRAPHY; MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; POLYETHYLENE GLYCOLS;

EID: 80052182569     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.05.016     Document Type: Review

References (90)

1. Pantaleo G., Graziosi C., Demarest J.F., Butini L., Montrone M., Fox C.H., Orenstein J.M., Kotler D.P., Fauci A.S. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:335-358.
2. Dowlatshahi K., Fan M., Snider H.C., Habib F.A. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997, 80:1188-1197.
3. Benedetti-Pancini P., Maneschi F., Scambia G., Greggi S., Cutillo G., D'Andrea G., Rabitti C., Coronetta F., Capelli A., Mancuso S. Lymphatic spread of cervical cancer: an anatomical and pathological study based on 225 radical hysterectomies with systemic pelvic and aortic lymphadenectomy. Gynecol. Oncol. 1996, 62:19-24.
4. Kodama Y., Inokuchi K., Okamura T. Tumor cell aggregation and mode of cancer spread in linitis plastics type of gastric carcinoma. Gann 1979, 70:721-729.
5. Xie Y., Bagby T.R., Cohen M.S., Forrest M.L. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Exp. Opin. Drug Deliv. 2009, 6:785-792.
6. Nishioka Y., Yoshino H. Lymphatic targeting with nanoparticulate system. Adv. Drug Deliv. Rev. 2001, 47:55-64.
7. Porter C.J.H., Charman S.A. Lymphatic transport of proteins after subcutaneous administration. J. Pharm. Sci. 2000, 89:297-310.
8. Porter C.J.H., Charman W.N. Intestinal lymphatic drug transport: an update. Adv. Drug Deliv. Rev. 2001, 50:61-80.
9. Moghimi S.M., Hawley A.E., Christy N.M., Gray T., Illum L., Davis S.S. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph-nodes. FEBS Lett. 1994, 344:25-30.
10. Moghimi S.M., Rajabi-Siahboomi A.R. Advanced colloid based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissue. Prog. Biophys. Mol. Biol. 1996, 65:221-249.
11. Oussoren C., Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Deliv. Rev. 2001, 50:143-156.
12. Oussoren C., Storm G. Lymphatic uptake and biodistributions of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethyleneglycol). Pharm. Res. 1997, 14:1479-1484.
13. Oussoren C., Velinova M., Scherphof G., van der Want J.J., van Rooijen N., Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection IV. Fate of liposomes in regional lymph nodes. Biochim. Biophys. Acta 1998, 1370:259-272.
14. Kobayashi H., Kawamoto S., Star R.A., Waldmann T.A., Tagaya Y., Brechbiel M.W. Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Res. 2003, 63:271-276.
15. Kaminskas L.M., Kelly B.D., McLeod V.M., Boyd B.J., Krippner G.Y., Williams E.D., Porter C.J.H. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. Mol. Pharm. 2009, 6:1190-1204.
16. Lei X.G., Jockusch S., Turro N.J., Tomalia D.A., Ottaviani M.F. EPR characterization of gadolinium(III)-containing-PAMAM-dendrimers in the absence and in the presence of paramagnetic probes. J. Colloid Interface Sci. 2008, 322:457-464.
17. Okuda T., Kawakami S., Akimoto N., Niidome T., Yamashita F., Hashida M. PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. J. Control. Release 2006, 116:330-336.
18. Zhu S., Hong M., Tang G., Qian L., Lin J., Jiang Y., Pei Y. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 2010, 31:1360-1371.
19. Tomalia D.A., Reyna L.A., Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans. 2007, 35:61-67.
20. Lim J., Chouai A., Lo S.T., Liu W., Sun X., Simanek E.E. Design, synthesis, characterization, and biological evaluation of triazine dendrimers bearing paclitaxel using ester and ester/disulfide linkages. Bioconjug. Chem. 2009, 20:2154-2161.
21. Lim J., Guo Y., Rostollan C.L., Stanfield J., Hsieh J.T., Sun X., Simanek E.E. The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers. Mol. Pharm. 2008, 5:540-547.
22. C.L. Waite, C.M. Roth, PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma, Bioconjug. Chem. 20 (2009) 1908-1916.
23. Singh P., Gupta U., Asthana A., Jain N.K. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug. Chem. 2008, 19:2239-2252.
24. Thomas T.P., Shukla R., Kotlyar A., Liang B., Ye J.Y., Norris T.B., Baker J.R. Dendrimer-epidermal growth factor conjugate displays superagonist activity. Biomacromolecules 2008, 9:603-609.
25. Backer M.V., Gaynutdinov T.I., Patel V., Bandyopadhyaya A.K., Thirumamagal B.T., Tjarks W., Barth R.F., Claffey K., Backer J.M. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol. Cancer Ther. 2005, 4:1423-1429.
26. Wang S.K., Liang P.H., Astronomo R.D., Hsu T.L., Hsieh S.L., Burton D.R., Wong C.H. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3690-3695.
27. Roy R., Baek M.G. Glycodendrimers: novel glycotope isosteres unmasking sugar coding. Case study with T-antigen markers from breast cancer MUC1 glycoprotein. J. Biotechnol. 2002, 90:291-309.
28. Jiang Y., Emau P., Cairns J., Flanara L., Morton W., McCarthy T., Tsai C. SPL7013 gel is a topical microbicide for prevention of vaginal transmission of SHIV89.61 in macaques. AIDS Res. Hum. Retroviruses 2005, 21. 207-013.
29. Kolhatkar R.B., Swaan P., Ghandehari H. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers. Pharm. Res. 2008, 25:1723-1729.
30. Ke W., Zhao Y., Huang R., Jiang C., Pei Y. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J. Pharm. Sci. 2008, 97:2208-2216.
31. Wiwattanapatapee R., Carreno-Gomez B., Malik N., Duncan R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system?. Pharm. Res. 2000, 17:991-998.
32. Sakthivel T., Toth I., Florence A.T. Distribution of a lipidic 2.5nm diameter dendrimer carrier after oral administration. Int. J. Pharm. 1999, 183:51-55.
33. Myc A., Douce T.B., Ahuja N., Kotlyar A., Kukowska-Latallo J., Thomas T.P., Baker J.R. Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates. Anticancer Drugs 2008, 19:143-149.
34. Bhadra D., Bhadra S., Jain S., Jain N.K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 2003, 257:111-124.
35. Lee C., Gillies E., Fox M., Guillaudeu S., Frechet L., Dy E., Szoka F. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl. Acad. Sci. U. S. A. 2006, 103. 16679-16654.
36. El-Sayed M., Kiani M.F., Naimark M.D., Hikal A.H., Ghandehari H. Extravasation of poly(amidoamine)(PAMAM) dendrimers across microvascular network endothelium. Pharm. Res. 2001, 18:23-28.
37. Kaminskas L.M., Kota J., McLeod V.M., Kelly B.D., Karellas P., Porter C.J.H. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats. J. Control. Release 2009, 140:108-116.
38. Bai S., Ahsan F. Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm. Res. 2009, 26:539-548.
39. Gajbhiye V., Kumar P.V., Sharma A., Agarwal A., Asthana A., Jain N.K. Dendrimeric nanoarchitectures mediated transdermal and oral delivery of bioactives. Ind. J. Pharm. Sci. 2008, 70:431-439.
40. Wang Z., Itoh Y., Hosaka Y., Kobayashi I., Nakano Y., Maeda I., Umeda F., Yamakawa J., Nishimine M., Suenobu T., Fukuzumi S., Kawase M., Yagi K. Mechanism of enhancement effect of dendrimer on transdermal drug permeation through polyhydroxyalkanoate matrix. J. Biosci. Bioeng. 2003, 96:537-540.
41. Chauhan A.S., Sridevi S., Chalasani K.B., Jain A.K., Jain S.K., Jain N.K., Diwan P.V. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J. Control. Release 2003, 90:335-343.
42. Cheng Y., Xu Z., Ma M., Xu T. Dendrimers as drug carriers: applications in different routes of drug administration. J. Pharm. Sci. 2008, 97:123-143.
43. Tam J.P., Spetzler J.C. Synthesis and application of peptide dendrimers as protein mimetics. Curr. Protoc. Protein Sci. 2001, Chapter 18. Unit18 15.
44. Chen H., Banaszak Holl M., Orr B.G., Majoros I., Clarkson B.H. Interaction of dendrimers (artificial proteins) with biological hydroxyapatite crystals. J. Dent. Res. 2003, 82:443-448.
45. Hecht S., Frechet J.M. Dendritic encapsulation of function: applying nature's site isolation principle from biomimetics to materials science. Angew. Chem. Int. Ed Engl. 2001, 40:74-91.
46. Kobayashi H., Kawamoto S., Jo S.K., Bryant H.L., Brechbiel M.W., Star R.A. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug. Chem. 2003, 14:388-394.
47. Kobayashi H., Kawamoto S., Saga T., Sato N., Hiraga A., Konishi J., Togashi K., Brechbiel M.W. Micro-MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: reference to pharmacokinetic properties of dendrimer-based MR contrast agents. J. Magn. Reson. Imaging 2001, 14:705-713.
48. Kobayashi H., Sato N., Hiraga A., Saga T., Nakamoto Y., Ueda H., Konishi J., Togashi K., Brechbiel M.W. 3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magn. Reson. Med. 2001, 45:454-460.
49. Kobayashi H., Kawamoto S., Sakai Y., Choyke P.L., Star R.A., Brechbiel M.W., Sato N., Tagaya Y., Morris J.C., Waldmann T.A. Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nanosize paramagnetic contrast agent. J. Natl. Cancer Inst. 2004, 96:703-708.
50. Wiener E.C., Brechbiel M.W., Brothers H., Mahin R.L., Gansow O.A., Tomalia D.A., Lauterbur P.C. Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn. Reson. Med. 1994, 31:1-8.
51. Venditto V.J., Regino C.S., Brechbiel M.W. PAMAM dendrimer based macromolecules as improved contrast agents. Mol. Pharm. 2005, 2:302-311.
52. Kobayashi H., Kawamoto S., Saga T., Sato N., Ishimori T., Konishi J., Ono K., Togashi K., Brechbiel M.W. Avidin-dendrimer-(1B4M-Gd)(254): a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. Bioconjug. Chem. 2001, 12:587-593.
53. Kobayashi H., Kawamoto S., Bernardo M., Brechbiel M.W., Knopp M.V., Choyke P.L. Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging. J. Control. Release 2006, 111:343-351.
54. Kobayashi H., Kawamoto S., Brechbiel M.W., Bernardo M., Sato N., Waldmann T.A., Tagaya Y., Choyke P.L. Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticle. Neoplasia 2005, 7:984-991.
55. Kobayashi H., Kawamoto S., Choyke P.L., Sato N., Knopp M.V., Star R.A., Waldmann T.A., Tagaya Y., Brechbiel M.W. Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. Magn. Reson. Med. 2003, 50:758-766.
56. Kobayashi H., Koyama Y., Barrett T., Hama Y., Regino C.A., Shin I.S., Jang B.S., Le N., Paik C.H., Choyke P.L., Urano Y. Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging. ACS Nano 2007, 1:258-264.
57. Kobayashi H., Ogawa M., Losaka N., Choyke P.L., Urano Y. Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labelled cancer cells and dendrimer-based optical agents. Nanomedicine (Lond.) 2009, 4:411-419.
58. McLennan D.N., Porter C.J.H., Charman S.A. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov. Today: Technol. 2005, 2:89-96.
59. Hawley A.E., Illum L., Davis S.S. Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm. Res. 1997, 14:657-661.
60. Mounzer R., Shakarin P., Papademetris X., Constable T., Ruddle N.H., Fahmy T.M. Dynamic imaging of lymphatic vessels and lymph nodes using a bimodal nanoparticulate contrast agent. Lymphat. Res. Biol. 2007, 5:151-158.
61. Porter C.J.H., Edwards G.A., Charman S.A. Lymphatic transport of proteins after S.C. injection: implications of animal model selection. Adv. Drug Deliv. Rev. 2001, 50:157-171.
62. Kota J., Machavaram K.K., McLennan D.N., Edwards G.A., Porter C.J.H., Charman S.A. Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. Drug Metab. Dispos. 2007, 35:2211-2217.
63. McLennan D.N., Porter C.J.H., Edwards G.A., Martin S.W., Heatherington A.C., Charman S.A. Lymphatic absorption is the primary contributor to the systemic availability of recombinant human erythropoietin following subcutaneous administration to sheep. J. Pharmacol. Exp. Ther. 2005, 313:345-351.
64. Williamson E.P., Sells R.A. The chyloesophageal fistula. A new approach to thoracic duct drainage. Transplantation 1986, 42:136-140.
65. Edwards G.A., Porter C.J.H., Caliph S.M., Khoo S.M., Charman W.N. Animal models for the study of intestinal lymphatic drug transport. Adv. Drug Deliv. Rev. 2001, 50:45-60.
66. Joyner W.L., Carter R.D., Raizes G.S., Renkin E.M. Influence of histamine and some other substances on blood-lymph transport of plasma protein and dextran in the dog paw. Microvasc. Res. 1974, 7:19-30.
67. Bocci V., Pessina G.P., Paulesu L., Nicoletti C. The lymphatic route. VI. Distribution of recombinant interferon-alpha 2 in rabbit and pig plasma and lymph. J. Biol. Response Mod. 1988, 7:390-400.
68. Trevaskis N.L., Charman W.N., Porter C.J.H. Lipid based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv. Drug Deliv. Rev. 2008, 60:702-716.
69. Yanez J.A., Wang S.W., Knemeyer I.W., Wirth M.A., Alton K.B. Intestinal lymphatic transport for drug delivery. Adv. Drug Deliv. Rev. 2011, 63:923-942. (this volume).
70. Boyd M., Risovic V., Jull P., Choo E., Wasan K.M. A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: cannulation of the mesenteric and thoracic lymph ducts within the rat. J. Pharmacol. Toxicol. Methods 2004, 49:115-120.
71. Greene E. Anatomy of the Rat 1963, Hagner, New York.
72. Flessner M.F., Parker R.J., Sieber S.M. Peritoneal lymphatic uptake of fibrinogen and erythrocytes in the rat. Am. J. Physiol. 1983, 244:H89-H96.
73. Kagan L., Gershkovich P., Mendelman A., Amsili S., Ezov N., Hoffman A. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat. Eur. J. Pharm. Biopharm. 2007, 67:759-765.
74. Charman S.A., Segrave A., Edwards G.A., Porter C.J.H. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J. Pharm. Sci. 2000, 89:168-177.
75. Reddy S.T., Berk D.A., Jain R.K., Swarts M.A. A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. J. Appl. Physiol. 2006, 101:1162-1169.
76. Lamka J., Jindrova O., Gallova S., Uhrova R., Kvetina J. Influence of the composition of rat central lymph on the pharmacokinetics (the steady state during infusion, bioavailability, absorption) of diazepam, studied in the blood and lymph. Physiol. Bohemoslov. 1990, 39:403-408.
77. Deak S.T., Csaky T.Z. Factors regulating the exchange of nutrients and drugs between lymph and blood in the small intestine. Microcirc. Endothelium Lymphatics 1984, 1:569-588.
78. Chen S.A., Sawchuk R.J., Brundage R.C., Horvath C., Mendenhall H.V., Gunther R.A., Braeckman R.A. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. J. Pharmacol. Exp. Ther. 2000, 293:248-259.
79. Powers M.R., Bell D.R. Initial equilibration of albumin and IgG in rabbit hind paw skin and lymph. Microvasc. Res. 1990, 40:230-245.
80. Engeset A., Aas M., Olszewski W., Sokolowski J. Time of exchange of 131I-labelled albumin between plasma and peripheral lymph in man. Lymphology 1979, 12:77-80.
81. Hovorka R., Nanjee M.N., Cooke C.J., Miller I.P., Olszewski W.L., Miller N.E. Mass kinetics of apolipoprotein A-1 in interstitial fluid after administration of intravenous apolipoprotein A-1/lecithin discs in humans. J. Lipid Res. 2010, 47:975-981.
82. Supersaxo A., Hein W.R., Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 1990, 7:167-169.
83. Charman S.A., Segrave A.M., Edwards G.A., Porter C.J.H. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J. Pharm. Sci. 2000, 89:168-177.
84. Charman S.A., McLennan D.N., Edwards G.A., Porter C.J.H. Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. Pharm. Res. 2001, 18:1620-1626.
85. McLennan D.N., Porter C.J.H., Edwards G.A., Brumm M., Martin S.W., Charman S.A. Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep. Pharm. Res. 2003, 20:1156-1162.
86. McLennan D.N., Porter C.J.H., Edwards G.A., Martin S.W., Heatherington A.C., Charman S.A. Lymphatic absorption is the primary contributor to the systemic availability of Epoietin alfa following subcutaneous administration to sheep. J. Pharmacol. Exp. Ther. 2005, 313:345-351.
87. Tripathi P.K., Khopade A.J., Nagaich S., Shrivastava S., Jain S., Jain N.K. Dendrimer grafts for delivery of 5-flurouracil. Pharmazie 2002, 57:261-264.
88. Talanov V.S., Regino C.A., Kobayashi H., Bernardo M., Choyke P.L., Brechbiel M.W. Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett. 2006, 6:1459-1463.
89. Hama Y., Bernardo M., Regino C.A., Koyama Y., Brechbiel M.W., Krishna M.C., Choyke P.L., Kobayashi H. MR lymphangiography using dendrimer-based contrast agents: a comparison at 1.5T and 3.0T. Magn. Reson. Med. 2007, 57:431-436.
90. Koyama Y., Talanov V.S., Bernardo M., Hama Y., Regino C.A., Brechbiel M.W., Choyke P.L., Kobayashi H. A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J. Magn. Reson. Imaging 2007, 25:866-871.